Candel Therapeutics (CADL) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed Candel Therapeutics (CADL) over the past year, gaining 91.5% versus a gain of 51.8%. Over five years, CADL leads with a +1.1% price change compared with -54.8% for SLN. Candel Therapeutics is the larger company by market cap ($760.6 million vs $612.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | SLN |
|---|---|---|
| Share price | $9.94 | $9.86 |
| Market cap | $760.59M | $612.84M |
| 1-day change | +2.90% | +3.57% |
| YTD return | +75.93% | +62.17% |
| 1-year return | +51.76% | +91.46% |
| 5-year return | +1.12% | -54.81% |
| EPS (TTM) | $-1.50 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.00 | $17.58 |
| 52-week low | $4.35 | $4.19 |
| Distance from 52-week high | -29.00% | -43.90% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +118.81% | +234.69% |
| Average volume | 1.21M | 1.14M |
| Shares outstanding | 76.52M | 62.15M |
| Employees | 55 | 88 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed CADL by 39.7 percentage points over the past year.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
CADL vs SLN FAQ
Which is bigger, Candel Therapeutics or Silence Therapeutics Plc American Depository Share?
Candel Therapeutics (CADL) is larger, with a market capitalization of $760.59M compared with $612.84M for Silence Therapeutics Plc American Depository Share (SLN).
Which stock has performed better over the past year, CADL or SLN?
SLN returned +91.46% over the past 12 months, compared with +51.76% for CADL (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and Silence Therapeutics Plc American Depository Share in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Candel Therapeutics and Biotechnology: Pharmaceutical Preparations for Silence Therapeutics Plc American Depository Share.